RxDoctor Payments Data

Edward Krowiak, MD

Otolaryngology · Carmel, INNPI 1023018546

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Lilly USA, LLC at 29.7% of the total. Reporting peaked in 2019 at $1,845 and has fallen 76.9% since, to $427 in 2025.

$5,295in general payments, 2019–2025

Across 61 payments — averaging $86.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • Stryker$1K
  • E.r. Squibb & Sons, L.L.C.$581
  • Johnson & Johnson$553
  • Medtronic$269
  • Intuitive Surgical$198
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$1,57530%
  • Travel & lodging$56111%
  • Food & beverage$3,15960%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,295 in reported general payments places this provider in the 80th percentile of 193 otolaryngology providers in Indiana.

See all otolaryngology providers in Indiana

Medicare billing

Part B allowed, 2024
$186,678
Medicare patients
442
Services billed
1,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium97$6,987
Pilocarpine Hcl34$2,184
Ipratropium Bromide58$1,925
Clotrimazole19$1,013
Armour ThyroidThyroid,pork14$1,001
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$745
Gabapentin72$631
Clindamycin Hcl23$503
Lidocaine Hcl ViscousLidocaine Hcl54$487
Fluticasone Propionate32$393
Oxycodone Hcl54$392
Pentoxifylline15$240
Levothyroxine Sodium56$209
Chlorhexidine Gluconate30$173
Prednisone55$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid, Armour Thyroid$40$7,988111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 193 otolaryngology providers in Indiana.

Other otolaryngology in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →